GLP-1s Are Reshaping Society And Corporate America Is Next [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
By 2025, that number doubled to 10 million. J.P. Morgan Global Research projects that 30 million Americans will be on GLP-1 treatment by 2030, not counting oral versions that remove injection and cold-chain barriers. The global incretin market is expected to reach $200 billion by 2030. The infrastructure supporting GLP-1 demand is evolving quickly. The Trump administration struck pricing agreements with Eli Lilly and Novo Nordisk, reducing costs through TrumpRx to $150 per month—down from list prices over $1,000. Amazon's One Medical recently launched a national GLP-1 program, with insurance pricing starting at $25 per month. These moves by the federal government and the world's largest retailer demonstrate how adoption is only poised to accelerate. As a result, the GLP-1 movement has become both a cultural signal and a story of human behavior, with its effects emerging in every aspect of life, including the workplace. The Workplace Is Not Immune To The GLP-1 Shift To understa
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price [Yahoo! Finance]Yahoo! Finance
- Is This Deal a Game Changer for Novo Nordisk? [Yahoo! Finance]Yahoo! Finance
- Is This Deal a Game Changer for Novo Nordisk? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website